Cytokinetics aims for broader Myqorzo approval next year after supportive trial data

Cytokinetics reported new data on its cardiac therapy Myqorzo, presented at a European scientific meeting. The results reinforce the drug’s efficacy in a specific heart muscle disorder.

The company believes the data could support an application for an expanded indication next year, which might double the product’s addressable market.

If the regulatory agency accepts the evidence, Myqorzo could reach a larger patient population, potentially enhancing Cytokinetics’ revenue prospects.